$0.07 EPS Expected for Exelixis, Inc. (EXEL)

November 1, 2017 – By Richard Conner

Investors sentiment increased to 1.33 in 2017 Q2. Its up 0.36, from 0.97 in 2017Q1. It increased, as 34 investors sold Exelixis, Inc. shares while 64 reduced holdings. 60 funds opened positions while 70 raised stakes. 229.51 million shares or 1.10% less from 232.07 million shares in 2017Q1 were reported.
Rathbone Brothers Public Ltd Company has invested 0.02% in Exelixis, Inc. (NASDAQ:EXEL). Weiss Multi has invested 0.05% in Exelixis, Inc. (NASDAQ:EXEL). Pillar Pacific Capital Limited Company invested in 0.06% or 18,000 shares. Bank & Trust Of New York Mellon holds 0.01% or 1.17M shares. Employees Retirement Association Of Colorado reported 52,101 shares. Moreover, Tekla Cap Mngmt Limited Liability Corp has 0.5% invested in Exelixis, Inc. (NASDAQ:EXEL). Renaissance Technology Ltd Liability owns 2.44 million shares. Moreover, Vanguard Gru Inc has 0.03% invested in Exelixis, Inc. (NASDAQ:EXEL) for 25.44 million shares. Hbk Invests Lp invested in 70,537 shares or 0.02% of the stock. State Board Of Administration Of Florida Retirement System invested in 379,607 shares or 0.03% of the stock. Bluecrest accumulated 222,241 shares. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL) for 15,110 shares. Swiss Bancshares has 486,900 shares. Polar Capital Llp invested in 0.06% or 190,000 shares. Schwab Charles Mngmt Inc stated it has 855,640 shares.

Since May 3, 2017, it had 0 insider purchases, and 3 selling transactions for $5.43 million activity. MORRISSEY MICHAEL also sold $4.62M worth of Exelixis, Inc. (NASDAQ:EXEL) shares. Another trade for 5,000 shares valued at $92,300 was sold by Haley Patrick J.. Another trade for 32,988 shares valued at $711,831 was sold by FELDBAUM CARL B.

Analysts await Exelixis, Inc. (NASDAQ:EXEL) to report earnings on November, 2. They expect $0.07 EPS, up 600.00 % or $0.06 from last year’s $0.01 per share. EXEL’s profit will be $20.59M for 88.89 P/E if the $0.07 EPS becomes a reality. After $0.08 actual EPS reported by Exelixis, Inc. for the previous quarter, Wall Street now forecasts -12.50 % negative EPS growth. About 1.22M shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 266.48% since November 1, 2016 and is uptrending. It has outperformed by 249.78% the S&P500.

Exelixis, Inc. (NASDAQ:EXEL) Ratings Coverage

Among 11 analysts covering Exelixis (NASDAQ:EXEL), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Exelixis had 34 analyst reports since January 19, 2016 according to SRatingsIntel. Deutsche Bank initiated the shares of EXEL in report on Thursday, November 3 with “Buy” rating. Deutsche Bank downgraded the stock to “Hold” rating in Thursday, August 3 report. The stock of Exelixis, Inc. (NASDAQ:EXEL) earned “Hold” rating by Oppenheimer on Thursday, August 3. The firm earned “Buy” rating on Sunday, September 10 by Piper Jaffray. On Wednesday, August 16 the stock rating was maintained by Oppenheimer with “Hold”. The rating was maintained by Piper Jaffray on Wednesday, August 16 with “Buy”. The rating was maintained by Cowen & Co with “Buy” on Thursday, August 3. The company was maintained on Thursday, September 7 by Stifel Nicolaus. On Thursday, July 13 the stock rating was initiated by SunTrust with “Buy”. The stock of Exelixis, Inc. (NASDAQ:EXEL) has “Hold” rating given on Monday, July 10 by Oppenheimer.

Exelixis, Inc. is a biopharmaceutical company. The company has market cap of $7.32 billion. The Firm is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. It has a 131.98 P/E ratio. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

More notable recent Exelixis, Inc. (NASDAQ:EXEL) news were published by: Seekingalpha.com which released: “Exelixis Stock Looks Promising Despite High Valuation Multiples” on October 25, 2017, also Fool.com with their article: “The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September” published on October 05, 2017, Fool.com published: “The case for Intra-Cellular Therapies” on October 21, 2017. More interesting news about Exelixis, Inc. (NASDAQ:EXEL) were released by: Seekingalpha.com and their article: “Exelixis – Elucidating The Ramifications Of The Celestial Trial” published on October 23, 2017 as well as Fool.com‘s news article titled: “Why Exelixis, Inc. Rose Higher Today” with publication date: October 16, 2017.